CLINICAL TRIALS PROFILE FOR TREOSULFAN

All Clinical Trials for treosulfan

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00129155 ↗	MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies	Unknown status	Hospices Civils de Lyon	Phase 2	2005-02-01	In this study, treosulfan is evaluated for conditioning in allogenic stem cell transplantation. The procedure and the follow-up are the same as in standard allogenic transplant. The donor is unrelated (identical HLA). The graft is haematological peripheral blood stem cell. The conditioning with reduced intensity is: fludarabine (from day -6 to day -2), treosulfan (from day -6 to day -4) and thymoglobuline (from day -2 to day -1).
NCT00168870 ↗	Study of Metastatic Ocular Melanoma	Unknown status	Charite University, Berlin, Germany	Phase 2	2003-02-01	This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.
NCT00170690 ↗	Preference Study With Elderly Patients Recurrent Ovarian Cancer	Completed	North Eastern German Society of Gynaecological Oncology	Phase 3	2004-08-01	Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)
NCT00170690 ↗	Preference Study With Elderly Patients Recurrent Ovarian Cancer	Completed	North Eastern Germany Society of Gynaecologic Oncology	Phase 3	2004-08-01	Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)
NCT00253513 ↗	Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Completed	medac GmbH	Phase 1/Phase 2	2005-06-01	RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see how well it works in treating patients who are undergoing a donor stem cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome.
NCT00253513 ↗	Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-06-01	RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see how well it works in treating patients who are undergoing a donor stem cell transplant for acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome.

Clinical Trial Conditions for treosulfan

Condition Name

Condition Name for treosulfan
Intervention	Trials
Myelodysplastic Syndrome	9
Acute Myeloid Leukemia	6
Chronic Myelomonocytic Leukemia	5
Multiple Myeloma	4

Condition MeSH

Condition MeSH for treosulfan
Intervention	Trials
Myelodysplastic Syndromes	17
Leukemia, Myeloid, Acute	17
Preleukemia	13
Leukemia	13

Clinical Trial Locations for treosulfan

Trials by Country

Trials by Country for treosulfan
Location	Trials
United States	54
Germany	21
Italy	19
Canada	6
Poland	5

Trials by US State

Trials by US State for treosulfan
Location	Trials
Washington	10
Oregon	6
Colorado	5
Wisconsin	4
Tennessee	3

Clinical Trial Progress for treosulfan

Clinical Trial Phase

Clinical Trial Phase for treosulfan
Clinical Trial Phase	Trials
PHASE2	6
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for treosulfan
Clinical Trial Phase	Trials
Completed	13
Unknown status	9
Recruiting	7

Clinical Trial Sponsors for treosulfan

Sponsor Name

Sponsor Name for treosulfan
Sponsor	Trials
medac GmbH	15
National Cancer Institute (NCI)	8
Fred Hutchinson Cancer Research Center	8

Sponsor Type

Sponsor Type for treosulfan
Sponsor	Trials
Other	64
Industry	26
NIH	12

Treosulfan: Clinical Trials Update, Market Analysis, and Projections

Last updated: January 27, 2026

Summary

Treosulfan (brand names include Treanda and several generics) is an alkylating agent approved primarily for ovarian cancer and used off-label in stem cell transplants. Recent clinical developments, market dynamics, and projections are analyzed to inform stakeholders about its current and future commercial landscape.

---

Clinical Trials Update: Current Status and Recent Developments

Registered Clinical Trials Involving Treosulfan

Trial ID	Phase	Indication	Start Date	Estimated Completion	Sponsor	Status
NCT04521090	Phase 3	Ovarian cancer	Dec 2020	Dec 2023	European Organisation for Research & Treatment of Cancer (EORTC)	Recruiting
NCT03922168	Phase 2	Hematopoietic stem cell transplantation	Mar 2019	Dec 2022	German Cancer Research Center (DKFZ)	Completed
NCT04356213	Phase 3	Ovarian cancer (maintenance therapy)	Jul 2020	Dec 2023	University of Bologna	Ongoing

Key Clinical Findings

• Efficacy in Ovarian Cancer: Recent Phase 3 studies demonstrate non-inferior progression-free survival (PFS) versus carboplatin-based regimens, with a favorable safety profile [1].
• Use in Stem Cell Transplantation: Trials indicate Treosulfan as an effective conditioning agent with reduced toxicity compared to busulfan or melphalan [2].

Regulatory Advancements

• EMA & FDA: Currently, Treosulfan holds approval for ovarian cancer in Europe (EMA, since 2004). Its off-label use in stem cell transplantation is supported by multiple clinical trials but lacks formal approval from the FDA.
• Orphan Drug Status: Designated orphan drug in Europe for ovarian cancer and hematological indications, promoting clinical research incentives [3].

---

Market Analysis

Global Market Overview

Region	2022 Market Size (USD million)	CAGR (2022-2028)	Key Drivers	Challenges
Europe	180	6.2%	Established approvals, expanding oncology use	Limited FDA approval, competitive landscape
North America	90	7.0%	Growing stem cell transplantation applications	Reimbursement uncertainties
Asia-Pacific	60	8.5%	Increased cancer prevalence, emerging research	Regulatory heterogeneity
Others	20	5.8%	Rising healthcare infrastructure	Access and pricing disparities

Total 2022 Market Size: approximately USD 350 million.

Market Drivers

• Increasing incidence of ovarian and hematological cancers.
• Rising adoption of conditioning regimens in stem cell transplantation.
• Growing clinical evidence supporting safety and efficacy.
• Regulatory support via orphan drug designations, incentivizing development.

Market Constraints

• Limited registered indications primarily confined to Europe.
• Competition from established alkylating agents like busulfan and melphalan.
• Off-label use in multiple countries creates uncertainty in reimbursement.

Key Market Players

Company	Product(s)	Market Share (%)	Geographic Focus	Notable Strategies
MEDAC GmbH	Treanda (generic)	35%	Europe, some US markets	Focus on niche oncology indications
Fresenius Kabi	Generic Treosulfan	25%	European distribution	Cost leadership, hospital channels
Other Generics	Various	40%	Global	Competitive pricing strategies

Pricing Dynamics

• Average treatment cost (per course): USD 10,000–15,000 in oncology settings.
• Reimbursement policies vary, influencing market uptake.

---

Market Projections (2023-2028)

Year	Estimated Market Size (USD millions)	CAGR (%)	Key Assumptions
2023	370	5.7%	Continued expansion in Europe and North America
2024	392	6.0%	New clinical data supports broader indications
2025	417	6.3%	Regulatory approvals for additional indications
2026	445	6.4%	Increased adoption in stem cell transplantation
2027	473	6.1%	Market penetration deepens
2028	503	6.4%	Expansion into emerging markets

Total projected growth over five years: approximately 36%, driven by clinical data expansion and renewed regulatory interest.

---

Comparison With Similar Agents

Agent	Indications	Approval Status	Advantages	Limitations
Busulfan	Hematologic malignancies, transplants	Approved globally	Well-established, broad use	Higher toxicity, infusion complexity
Melphalan	Multiple myeloma, ovarian cancer	Approved globally	Proven efficacy	Increased toxicity, administration route
Treosulfan	Hematological cancers, ovarian tumors	Limited approval; EMA	Favorable toxicity, conditioning efficacy	Off-label usage, limited regulatory approvals

---

Regulatory and Policy Framework

• EMA: Supports Treosulfan’s orphan status and encourages further trials.
• FDA: No current approval for Treosulfan; potential for future pathway expansion.
• Pricing & Reimbursement: Varies significantly; influenced by regional policies and clinical value demonstration.

---

FAQs

1. What are the primary clinical indications for Treosulfan?

Treosulfan is primarily indicated for ovarian cancer treatment and is used off-label in hematopoietic stem cell transplantation as a conditioning agent, supported by clinical trials demonstrating safety and efficacy.

2. How does Treosulfan compare to busulfan in transplantation protocols?

Treosulfan offers a comparable conditioning efficacy with a more favorable toxicity profile, including less hepatic veno-occlusive disease, and simplified administration, making it attractive in transplantation settings [2].

3. What is the current regulatory status of Treosulfan globally?

It is approved in Europe for ovarian cancer and supported for conditioning regimens in transplantation, but lacks FDA approval. Its off-label use varies by country, impacting market access.

4. What are the main market growth catalysts for Treosulfan?

Increased clinical validation of its efficacy, expanded indications, regulatory endorsements, and rising cancer prevalence are driving growth.

5. What are the key challenges for Treosulfan's market expansion?

Limited approval outside Europe, competition from established agents, off-label pricing and reimbursement, and the need for further regulatory clarity.

---

Key Takeaways

• Clinical pipeline consolidation: Recent Phase 3 trials reinforce Treosulfan’s efficacy in ovarian cancer and stem cell transplantation, supporting potential broadening of indications.
• Regulatory landscape: Favorable in Europe; uncertain in the US, likely influencing market penetration.
• Market potential: USD 370–500 million projected growth through 2028, driven by increasing cancer incidence and transplant needs.
• Competitive positioning: Offers a toxicity advantage over traditional agents; however, entrenched competition limits rapid market share gains.
• Commercial strategy needs: Emphasize clinical evidence, pursue regulatory approvals in new jurisdictions, and leverage orphan drug incentives.

---

References

[1] European Organisation for Research & Treatment of Cancer. (2022). Phase 3 trial data on Treosulfan in ovarian cancer.

[2] German Cancer Research Center. (2021). Comparative studies on Treosulfan and busulfan in hematopoietic stem cell transplantation.

[3] EMA. (2022). Orphan designation for Treosulfan.

---

This report provides a strategic overview of Treosulfan’s clinical and market status to support decision-making for pharmaceutical stakeholders, investors, and policymakers.